Page 117 - CIBERER-2015-eng

Most relevant scientific articles
Research Groups
martin-higueras c, luis-lima s, salido e. Glycolate oxi- dase is a safe and efficient target for substrate reduction therapy in a mouse model of Primary Hyperoxaluria Type I. Mol Ther. 2015 Dec 22. PMID: 26689264.
luis-lima s, marrero-miranda d, gonZáleZ-rinne a, torres a, gonZáleZ-Posada Jm, rodrígueZ a, salido e, aldea-Perona a, gasPari F, carrara F, gómeZ-gerique Ja, negrín-mena n, PéreZ-tamaJón l, gonZáleZ-rinne F, JiméneZ-hernándeZ h, JiméneZ-sosa a, Porrini e. Es- timated Glomerular Filtration Rate in Renal Transplanta- tion: The Nephrologist in the Mist. Transplantation. 2015 Dec;99(12):2625-33. PMID: 26247554.
Highlights
TWO EUROPEAN GRANT APPLICATIONS (H2020):
One as leader (Glycolate oxidase inhibitors for the treatment of Primary Hyperoxaluria) and another as partner (OxyGene: Gene therapy for the treatment of Primary Hyperoxaluria); one made it to the second round of evaluation, but none was funded.
ERARE PROJECT: ERAdicatPH (proposal-196): Understanding primary hyperoxaluria type 1 to- wards the development of innovative therapeutic strategies. Financed: 679124 euros; partner #2: 39930 euros. 2016-2018.
mesa-torres n, tomic n, alBert a, salido e, PeY al. Mo- lecular recognition of PTS-1 cargo proteins by Pex5p: impli- cations for protein mistargeting in primary hyperoxaluria. Biomolecules. 2015 Feb 13;5(1):121-41. PMID: 25689234
hernándeZ d, triñanes J, salido e, Pitti s, ruFino m, gonZáleZ-Posada Jm, torres a. Artery Wall Assessment Helps Predict Kidney Transplant Outcome. PLoS One. 2015 Jun 12;10(6):e0129083. PMID: 26066045
esPino m, Font-llitJós m, Vilches c, salido e, Prat e, lóPeZ de heredia m, Palacín m, nunes V. Digenic Inher- itance in Cystinuria Mouse Model. PLoS One. 2015 Sep 11;10(9):e0137277. PMID: 26359869
MOST RELEVANT RESEARCH RESULTS:
Preclinical studies (genetically modified mouse) on the safety and efficacy of a substrate reduction therapy approach to treat primary hyperoxalurias by inhibiting glycolate oxidase in one of two ways: siR- NA and small molecules. Collaboration with Dicerna Pharmaceuticals to launch a clinical trial based on Glycolate Oxidase siRNA nanoparticles.
Institution: Fundación Canaria de Investigación Sanitaria (FUNCANIS)
Contact: Hospital Universitario de Canarias · Ofra, s/n. La Cuesta. 38820 La Laguna · Tel.: 922 679 731 E.mail: [email protected]
CIBERER I Annual report 2015 I 117